60 Degrees Pharmaceuticals (SXTP) Revenue (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Revenue of $162092.0 for Q1 2026, down 0.89% year-over-year from $163552.0 in Q1 2025, and down 46.57% quarter-over-quarter from $303385.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Revenue (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Revenue for 5 consecutive years, with $162092.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 0.89% year-over-year to $162092.0; the TTM figure through Mar 2026 stood at $1.0 million (up 50.88% YoY), while the FY2025 annual figure was $1.0 million, up 65.49% from the prior year.
- Revenue fell to $162092.0 in Q1 2026 per SXTP's latest filing, from $303385.0 in the prior quarter.
- Across five years, Revenue topped out at $504613.0 in Q2 2022 and bottomed at $17172.0 in Q1 2023.
- Historically, Revenue has averaged $212523.5 across 5 years, with a median of $163552.0 in 2025.
- Annual changes were most pronounced in 2023 — Revenue tumbled 69.56% — and 2024, when it jumped 515.39%.
- 60 Degrees Pharmaceuticals' Revenue stood at $168185.0 in 2022, then soared by 61.63% to $271833.0 in 2023, then decreased by 11.11% to $241635.0 in 2024, then advanced by 25.56% to $303385.0 in 2025, then plunged by 46.57% to $162092.0 in 2026.
- Business Quant data shows SXTP's Revenue at $162092.0 in Q1 2026, $303385.0 in Q4 2025, and $437602.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 674.14 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.01 Mn | 1.99 Mn | 56,798.00 | 207,898.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162,092.00 |
| Dec 31, 2025 | 303,385.00 |
| Sep 30, 2025 | 437,602.00 |
| Jun 30, 2025 | 100,932.00 |
| Mar 31, 2025 | 163,552.00 |
| Dec 31, 2024 | 241,635.00 |
| Sep 30, 2024 | 135,293.00 |
| Jun 30, 2024 | 124,972.00 |
| Mar 31, 2024 | 105,674.00 |
| Dec 31, 2023 | 271,833.00 |
| Sep 30, 2023 | 51,188.00 |
| Jun 30, 2023 | 399,725.00 |
| Mar 31, 2023 | 17,172.00 |
| Sep 30, 2022 | 168,185.00 |
| Jun 30, 2022 | 504,613.00 |